Back    Zoom +    Zoom -
HENGRUI PHARMA's Drugs Receive Approval in CN for Combined Clinical Trials
Recommend
4
Positive
7
Negative
2
HENGRUI PHARMA (01276.HK) announced that the group, together with its subsidiaries Suzhou Suncadia Biopharmaceuticals and Shanghai Shengdi Pharmaceutical, has received approval from China's National Medical Products Administration for the clinical trial applications of SHR-A1811 for injection, Adebrelimab injection, and Famitinib malate capsules.

Clinical trials are set to commence soon.

Related NewsCICC Lists A-shr Companies that May List on H-shr Mkt Soon (Table)

AAStocks Financial News
  • Remark
  • (1) HK Indices are real time
Home|RT Quote|Market|News|Indices
Feedback|Disclaimer
View: Mobile|Desktop
Lang: 繁|简|EN
Back To Top
Contact Us
Email: support@aastocks.com